Free Access
Med Sci (Paris)
Volume 25, Number 12, Décembre 2009
Anticorps monoclonaux en thérapeutique
Page(s) 1113 - 1115
Section II - La réalité clinique
Published online 15 December 2009
  1. Polman CH, O’Connor P, Havrdova E, et al. A randomized, placebo-controlled trial of Natalizumab for relapsing multiple sclerosis. N Engl J Med 2006; 354 : 899–910. [Google Scholar]
  2. Yousry TA, Major EO, Ryschkewitsch C, et al. Evaluation for progressive multifocal leuko-encephalopathy in patients treated with natalizumab. N Engl J Med 2006; 355 : 924–33. [Google Scholar]
  3. Hauser SL, Johnston SC. Balancing risk and reward: the question of natalizumab. Ann Neurol 2009; 66 : A7–8. [Google Scholar]
  4. Coles AJ, Compston DA, Compston DA, et al. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. CAMMS223 trial investigators. N Engl J Med 2008; 359 : 1786–801. [Google Scholar]
  5. Hawker K, O’Connor P, Freedman MS, et al. Rituximanb in patients with primary progressive multiple sclerosis: results of a randomized double blind placebo-controlled multicenter trial. Ann Neurol 2009; 66 : 460–71. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.